Company Profile
Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company provides the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery.
Its portfolio also includes KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases, and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH CTP) for assisted reproduction.
It also develops KJ101, a recombinant human chymotrypsin developed through synthetic biology that is in Phase 2 clinical trials. Its portfolio also includes KJ015, a bispecific anti HER2 antibody, BJ007, a subcutaneous formulation of ceftriaxone sodium for the treatment of bacterial infections, BJ009, a first generation cephalosporin antibiotic for treating bacterial infections
Including of the skin, bones, joints, reproductive organs, blood, heart valves, respiratory tract, biliary tract, and urinary tract, and SJ04, a recombinant human chorionic gonadotropin (hCG) that can be used in assisted reproductive procedures to accelerate follicle maturation and induce ovulation.
These product candidates are in Phase 1 clinical trials. Additionally, it is developing BJ045, a subcutaneously administered anti CD20 antibody. Its portfolio also includes BJ047, a subcutaneously administered anti CD154 antibody, BJ008, a subcutaneous formulation of cefoperazone sodiumยsulbactam sodium to treat bacterial infections, and BJ044, a serine protease inhibitor with broad anti inflammatory properties.
These product candidates are in the preclinical stage. It also licenses its intellectual property and deliverables and provides technical services. Founded in 2019, Shanghai Bao Pharmaceuticals is based in Shanghai, China.